Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Says Q2 Revenue Grew 20 Percent as Loss Swings to Profit

NEW YORK (GenomeWeb News) – Luminex today said total second-quarter revenues increased 25 percent as a net loss turned into a profit.
 
Receipts for the three months ended June 30 increased to $13 million from $10.7 million year over year. The company said it generated $5.8 million from the sale of 205 Luminex Systems in the period.
 
R&D costs increased 20 percent to $1.8 million from $1.5 million from the comparable quarter a year ago.
 
Luminex also reported a net income of $271,000 for the second quarter compared to a net loss of $363,000 last year.
 
Luminex had $24 million in cash and cash equivalents as of June 30.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.